Viatris will spend as much as $335 million to settle opioid-related claims against the Canonsburg-based pharmaceutical company. The proposed settlement over nine years would come in the form of ...

Viatris (NASDAQ:VTRS) has agreed to pay up to a maximum of $335M as part of a nationwide settlement to resolve opioid-related claims. The amount consists of annual payments over a nine-year period ...

Viatris (VTRS) has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries. The ...

Viatris to pay up to $335 million over nine years to settle opioid claims nationwide. The company has accrued $270 million for potential resolution, noted in its 2024 10-K filing. Markets are ...

With a market cap of $14.8 billion, Viatris Inc. (VTRS) is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a former Pfizer division. Headquartered in ...

Viatris (VTRS, Financials) will pay up to $335 million in annual installments over nine years to settle opioid-related claims from U.S. states, local governments, and tribal entities, the company ...

Viatris, Inc. VTRS announced that it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and tribes against it and certain of its ...